Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab in Moderate to Severe Plaque Psoriasis (PHOENIX 2)
NCT00307437Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- May 2005
- Primary completion
- Dec 2006
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of ustekinumab in plaque psoriasis (3 arms), sponsored by Johnson & Johnson. Primary endpoint: Proportion of Participants Achieving >= 75% Improvement in Psoriasis Area and Severity Index at 12 weeks. Started May 2005; status: completed.
02
Drugs
ustekinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00307437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00307437.